Hot Investor Mandate: Evergreen Investor Allocates Up to $20M, Focusing on Clinical-Stage Therapeutics, Near-Commercialization Medical Devices, and Healthtech

August 11, 2026 ~ Next Phase Admin ~ Leave a comment

A Europe-based investment group invests through an evergreen structure. The firm typically deploys approximately $2–$20M per company and invests primarily in private companies with a focus on the Nordic region. Investments are generally structured as equity, although convertible loans may also be considered. The firm has a long track record of supporting healthcare companies through growth and public-market exits and typically seeks a small number of new investments each year.

Within life sciences and healthcare, the firm focuses on therapeutics, medical technology, and healthtech. For therapeutics, the firm generally targets clinical-stage drug development companies and has particular interest in oncology and orphan or rare diseases. Within medical technology, the firm considers all device classes but generally favors companies approaching commercialization. In healthtech, the firm prioritizes solutions with demonstrated willingness to pay and sustainable business models, with a particular preference for B2B opportunities.

From a company and management team perspective, the firm seeks private companies with strong development or commercial potential and takes an active approach following investment. The firm generally seeks board representation and works closely with portfolio companies as they progress through clinical development, commercialization, growth, and potential exit opportunities.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

More Investors. More Opportunities. More Momentum.

August 11, 2026August 11, 2026 ~ Next Phase Admin ~ Leave a comment

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Investor interest in RESI Boston is building quickly as the launch of the RESI partnering platform approaches on Monday, August 17. With partnering just days away, investor registrations are expected to accelerate further as firms prepare to identify companies and begin scheduling one-on-one meetings.

In five days of investor registration, more than 30 investor firms signed up to participate, reinforcing RESI’s position as one of the premier partnering events for early-stage life science companies seeking capital and strategic partnerships.

Recently Confirmed Investors (Last 5 Days)

Explore the full RESI Boston investor list here.

These new registrations join a growing community of investors from across venture capital, corporate venture, family offices, angel groups, foundations, and strategic investment organizations, creating even more opportunities for meaningful one-on-one meetings.

🏷️ Save $300 on RESI Boston Registration

Secure your pass before Early Bird rates end this Friday, August 14th to get full access to investor partnering!

Already, more than 200 investors representing over 150 global investor firms have registered for RESI Boston, with additional investors continuing to join each week.

As the investor roster continues to grow, so do the opportunities to connect with the partners who can help move your company forward.

Register now to join one of the industry’s most active life science partnering events. Early Bird pricing ends Friday, August 14, giving attendees one last opportunity to save $300 before standard rates take effect.

Hot Investor Mandate: Asia-Based Life Science Venture Capital Investing in Pre-A to Series B Therapeutics, Devices, and Diagnostics Companies Across Global Markets

August 4, 2026 ~ Next Phase Admin ~ Leave a comment

This investment firm is headquartered in Asia with offices in North America and focuses on early-stage investments in life sciences and healthcare. The firm typically participates in pre-Series A to Series B financing rounds, with initial investment sizes ranging from several hundred thousand dollars to several million dollars and the potential for follow-on investments. The firm seeks opportunities primarily in Europe, as well as North America and the United Kingdom. The firm is open to both leading and co-investing in financing rounds.

The firm is interested in therapeutics, medical devices, and diagnostics. The firm is open to evaluating digital health and AI-related companies but has limited investment activity in these areas to date. The firm takes an opportunistic approach across subsectors and indications, with areas of interest including immunology, immuno-oncology, central nervous system disorders, and kidney-related diseases.

For therapeutics, the firm considers opportunities from Phase I and beyond, particularly companies with proof-of-concept data or clinical validation supporting their technologies. For medical devices and diagnostics, the firm generally seeks more mature companies with products or prototypes in development, along with clear regulatory approval strategies.

The firm does not have specific requirements for management teams but prefers to work with founding teams that have prior entrepreneurial experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Mandate: US-Based Family Office Investing in Therapeutics, Medical Devices, and Diagnostics Companies with Strong Social Impact Focus Addressing Underserved Medical Needs

August 4, 2026 ~ Next Phase Admin ~ Leave a comment

This single-family office represents private family interests in the United States. The firm is flexible in terms of investment size but generally looks to invest at least several hundred thousand dollars per round, depending on round size and anticipated capital requirements. The firm prefers Series A and later-stage companies, while pre-Series A opportunities are considered depending on technology maturity. Currently, the firm invests primarily in companies based in North America.

The firm seeks breakthrough technologies with a strong social impact focus in the therapeutics, medical devices, and diagnostics sectors that address underserved medical needs or provide innovative and disruptive approaches to existing medical procedures and treatments. Areas of particular interest include optical and sound-based technologies, devices that reduce reliance on drug-based treatments, orthopedics, gene and nucleic acid-based therapies, immuno-oncology, and technologies addressing sensory loss.

The firm reviews co-investment opportunities in private companies and, on an opportunistic basis, may consider investments in micro- and small-cap public companies as a direct investor. The firm seeks companies that have completed seed financing and have reached key intellectual property milestones, including allowance of claims by relevant patent authorities.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Mandate: US-Based Healthcare VC Focused on Medical Technologies and Digital Health Solutions, Investing Across Early- and Late-Stage Opportunities

August 4, 2026 ~ Next Phase Admin ~ Leave a comment

This venture capital firm was founded in the mid-2000s and manages approximately $100 million in assets across multiple funds. The firm makes equity investments ranging from several hundred thousand dollars to several million dollars, with additional capital reserved for follow-on rounds. The firm invests in companies located throughout North America and Europe and plans to make several new investments over the next year. The firm invests in both early-stage companies and later-stage commercial growth opportunities.

The firm focuses on companies developing medical devices, diagnostics, and healthcare IT products, with an emphasis on capital-efficient technologies that can reach the market quickly and reduce the cost of delivering quality healthcare. The firm is open to a broad range of subsectors and indications within medical technology, with particular interest in technologies related to cardiovascular health and neurological applications.

The firm seeks companies with skilled and experienced management teams. The firm generally looks to take board seats in portfolio companies after investment and plays an active role in supporting company growth and strategic decisions.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Hot Investor Mandate: CVC Arm of Global Pharmaceutical Company Focuses on Early-Stage Therapeutics and Technologies Enhancing Drug Discovery and Pharmaceutical R&D

August 4, 2026 ~ Next Phase Admin ~ Leave a comment

This corporate venture fund was established in 2023 to invest in innovative life sciences companies developing technologies strategically aligned with its parent pharmaceutical company’s long-term research and development priorities. Headquartered in the United States, the fund manages evergreen capital and invests globally, with a primary focus on companies based in North America, Europe, and Asia. The fund typically makes initial investments of several million dollars and has the capacity to provide additional follow-on capital over the life of a portfolio company. The fund seeks to support breakthrough scientific innovation while building long-term strategic relationships with emerging biotechnology companies through minority equity investments.

The fund focuses on early-stage therapeutics, enabling platform technologies, and digital technologies that can enhance drug discovery and pharmaceutical R&D. Areas of particular interest include advanced therapeutic modalities, targeted drug discovery approaches, next-generation biologics, RNA-based technologies, and platform technologies capable of generating multiple therapeutic programs across diverse disease areas. Within digital technologies, the fund primarily seeks artificial intelligence, machine learning, computational biology, and data science applications that improve target identification, drug design, lead optimization, and other aspects of drug discovery and development. The fund focuses primarily on preclinical and early clinical-stage opportunities and does not invest in medical devices, diagnostics, healthcare services, or patient-centric digital health applications.

The fund invests in privately held biotechnology companies and does not maintain rigid management team requirements. The fund typically participates as a minority investor alongside other life sciences investors and generally does not lead financing rounds or require board representation. Instead, the fund seeks collaborative relationships with innovative companies whose technologies have strategic relevance to its research organization while allowing portfolio companies to remain operationally independent.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

Meet the First Believers: The Investors Behind Tomorrow’s Breakthrough Companies

August 4, 2026 ~ Next Phase Admin ~ Leave a comment

By Momo Yamamoto, Senior Investor Research Analyst, LSN

Every successful life science company has a defining moment in its fundraising journey. Long before a major venture capital round or strategic partnership, there is often an investor willing to take the very first leap of faith.

At 9:00 AM on Wednesday, September 23, Day 2 of RESI Boston 2026 begins with one of the conference’s most valuable discussions for early-stage founders: The First Believers: The Investors Behind Tomorrow’s Breakthrough Companies.

Securing that first investment is about much more than capital. Early investors provide critical validation, open doors to strategic relationships, and help companies build the momentum needed to attract future financing. Understanding how these investors think can give entrepreneurs a significant advantage as they prepare for fundraising.

This panel brings together accomplished investors and innovation leaders who regularly evaluate breakthrough technologies at their earliest stages:

Renaud Jacquemart Omnium Global (Moderator)	Sam Gussman-Toh ARPA-H	William Hsu, PhD NuFund Venture Group
Rohit Jain HBS Alumni Angels of Northern California	Dushyant Pathak Autobahn Labs

These panelists represent a diverse range of perspectives across venture creation, angel investing, government-supported innovation, and early-stage venture capital. Collectively, they helped identify and support companies long before they became widely recognized.

During the discussion, attendees will gain insight into what separates promising startups from investable opportunities. The panel will explore the characteristics investors look for in founding teams, the technical and commercial milestones that inspire confidence, and the common mistakes entrepreneurs make when approaching investors during the earliest stages of fundraising.

The conversation will also address how startups can build credibility before institutional financing, demonstrate meaningful progress with limited resources, and develop fundraising strategies that position them for long-term success.

For founders preparing to raise their first outside capital, this session offers a rare opportunity to hear directly from the investors who are often the first to believe in transformative science and technology.

Whether you are refining your investment story, preparing for investor meetings, or mapping out your fundraising roadmap, The First Believers panel will provide practical insights that can help shape your next steps.

Don’t miss this opportunity to kick off Day 2 of RESI Boston with an inside look at how early-stage investors identify the breakthrough companies of tomorrow.